Sumita Verma
YOU?
Author Swipe
View article: Correction: Palliative long-term abdominal drains vs. large volume paracentesis for refractory ascites secondary to cirrhosis: protocol for a definitive randomised controlled trial (REDUCe2 study)
Correction: Palliative long-term abdominal drains vs. large volume paracentesis for refractory ascites secondary to cirrhosis: protocol for a definitive randomised controlled trial (REDUCe2 study) Open
View article: Palliative long-term abdominal drains vs. large volume paracentesis for refractory ascites secondary to cirrhosis: protocol for a definitive randomised controlled trial (REDUCe2 study)
Palliative long-term abdominal drains vs. large volume paracentesis for refractory ascites secondary to cirrhosis: protocol for a definitive randomised controlled trial (REDUCe2 study) Open
View article: POS1153 SAFETY AND EFFICACY OF MONTHLY DOSING OF PEGLOTICASE (EVERY 4 WEEKS) WITH METHOTREXATE CO-ADMINISTRATION IN PATIENTS WITH UNCONTROLLED GOUT: PHASE 4 FORWARD OPEN-LABEL TRIAL
POS1153 SAFETY AND EFFICACY OF MONTHLY DOSING OF PEGLOTICASE (EVERY 4 WEEKS) WITH METHOTREXATE CO-ADMINISTRATION IN PATIENTS WITH UNCONTROLLED GOUT: PHASE 4 FORWARD OPEN-LABEL TRIAL Open
View article: ABS0756 SHORTER INFUSION DURATION OF PEGLOTICASE COADMINISTERED WITH METHOTREXATE IN PATIENTS WITH UNCONTROLLED GOUT: SECONDARY AND EXPLORATORY ENDPOINTS OF THE AGILE TRIAL
ABS0756 SHORTER INFUSION DURATION OF PEGLOTICASE COADMINISTERED WITH METHOTREXATE IN PATIENTS WITH UNCONTROLLED GOUT: SECONDARY AND EXPLORATORY ENDPOINTS OF THE AGILE TRIAL Open
View article: Palliative Long-term Abdominal Drains vs. Large Volume Paracentesis for refractory ascites secondary to cirrhosis: study protocol for a randomised controlled trial
Palliative Long-term Abdominal Drains vs. Large Volume Paracentesis for refractory ascites secondary to cirrhosis: study protocol for a randomised controlled trial Open
Background Ascites remains the most common complication of cirrhosis and a frequent reason for hospitalisation in advanced chronic liver disease (ACLD). Ascites is associated with significant symptom burden, caregiver workload and poor hea…
View article: Comparative Evaluation of Various Diagnostic Modalities for Laboratory Diagnosis of Dengue - A Study Done in a Tertiary Level Hospital of Western Rajasthan
Comparative Evaluation of Various Diagnostic Modalities for Laboratory Diagnosis of Dengue - A Study Done in a Tertiary Level Hospital of Western Rajasthan Open
Dengue fever is currently the most important arthropod borne viral disease due to its potential for extensive outbreaks of life-threatening disease. Dengue is an acute viral infection with potentially fatal complications. Early and accurat…
View article: A novel multisite model to facilitate hepatitis C virus elimination in people experiencing homelessness
A novel multisite model to facilitate hepatitis C virus elimination in people experiencing homelessness Open
In people experiencing homeless, we found a high prevalence of HCV, alcohol, and substance misuse including overdoses and mental health issues. Despite this, an integrated and decentralised service resulted in excellent linkage to care wit…
View article: Outcomes in Cirrhosis-Related Refractory Ascites with Emphasis on Palliative Care: Single-Centre Experience and Literature Review
Outcomes in Cirrhosis-Related Refractory Ascites with Emphasis on Palliative Care: Single-Centre Experience and Literature Review Open
View article: Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated‐Test‐stage Treat study final outcomes
Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated‐Test‐stage Treat study final outcomes Open
Achieving hepatitic C virus (HCV) elimination requires linking people who use drugs (PWUD) into care. We report final direct‐acting antivirals (DAAs)‐based outcomes from the Integrated‐Test‐stage ‐Treat (ITTREAT) study. Project ITTREAT (20…
View article: Antibiotic prophylaxis in palliative patients with cirrhosis: Stewardship or gatekeeping?
Antibiotic prophylaxis in palliative patients with cirrhosis: Stewardship or gatekeeping? Open
To the editor: Crocombe et al's1 evidence-based review of antibiotic prophylaxis in decompensated cirrhosis is commendable given the high morbidity and mortality associated with antimicrobial resistance, and we await the results of the ASP…
View article: Developing a generic business case for an advanced chronic liver disease support service
Developing a generic business case for an advanced chronic liver disease support service Open
Introduction Liver disease deaths are rising, but specialist palliative care services for hepatology are limited. Expansion across the NHS is required. Methods We surveyed clinicians, patients and carers to design an ‘ideal’ service. Using…
View article: Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease
Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease Open
Objectives Maraviroc may reduce hepatic inflammation in people with HIV and non-alcoholic fatty liver disease (HIV-NAFLD) through CCR5-receptor antagonism, which warrants further exploration. Methods We performed an open-label 96-week rand…
View article: Palliative clinical trials in advanced chronic liver disease: Challenges and opportunities
Palliative clinical trials in advanced chronic liver disease: Challenges and opportunities Open
Patients with advanced chronic liver disease have a complex symptom burden and many are not candidates for curative therapy. Despite this, provision of palliative interventions remains woefully inadequate, with an insufficient evidence bas…
View article: AB1255 PEGLOTICASE + METHOTREXATE COTHERAPY IN UNCONTROLLED GOUT PATIENTS WITH PRIOR PEGLOTICASE MONOTHERAPY FAILURE: FINDINGS OF THE ADVANCE OPEN-LABEL TRIAL
AB1255 PEGLOTICASE + METHOTREXATE COTHERAPY IN UNCONTROLLED GOUT PATIENTS WITH PRIOR PEGLOTICASE MONOTHERAPY FAILURE: FINDINGS OF THE ADVANCE OPEN-LABEL TRIAL Open
View article: POS0513 QUALITY OF LIFE AND CLINICAL GOUT ASSESSMENT CHANGES IN UNCONTROLLED GOUT PATIENTS UNDERGOING PEGLOTICASE THERAPY AS PART OF THE MIRROR RANDOMIZED CONTROLLED TRIAL
POS0513 QUALITY OF LIFE AND CLINICAL GOUT ASSESSMENT CHANGES IN UNCONTROLLED GOUT PATIENTS UNDERGOING PEGLOTICASE THERAPY AS PART OF THE MIRROR RANDOMIZED CONTROLLED TRIAL Open
Background Refractory/uncontrolled gout can severely limit physical function and impact patient quality of life [1,2]. Unfortunately, limited treatment options exist for patients intolerant of or refractory to oral urate-lowerin…
View article: Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans
Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans Open
View article: Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK
Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK Open
Background Previous studies show the uptake of biannual ultrasound (US) surveillance in patients with cirrhosis is suboptimal. Here, our goal was to understand in broader terms how surveillance is being delivered to cirrhosis patients with…
View article: Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document
Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document Open
Palliative care remains suboptimal in advanced cirrhosis, in part relating to a lack of evidence-based interventions. Ascites remains the most common cirrhosis complication resulting in hospitalisation. Many patients with refractory ascite…
View article: Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study
Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study Open
Background/aims Community‐based assessment and management of chronic liver disease (CLD) in people who are homeless (PWAH) remain poorly described. We aimed to determine prevalence/predictors of CLD in PWAH and assess the performance of no…
View article: PWE-34 Evaluating the non-viral liver disease burden in people living with HIV and abnormal liver enzymes
PWE-34 Evaluating the non-viral liver disease burden in people living with HIV and abnormal liver enzymes Open
Introduction Liver disease in the absence of viral hepatitis co-infection is a growing problem in people living with HIV (PLWH). Likely contributors include alcohol excess, metabolic syndrome (MS), and hepatotoxic antiretrovirals (ARV). We…
View article: PWE-11 Can the online shopping model ‘lock-box delivery’ improve Hepatitis C treatment access amongst vulnerable adults?
PWE-11 Can the online shopping model ‘lock-box delivery’ improve Hepatitis C treatment access amongst vulnerable adults? Open
Introduction Hepatitis C virus (HCV) predominantly affects vulnerable and disenfranchised individuals, including people who use drugs (PWUD) and people who are homeless (PWAH); our prior work shows only 5% attend hospital appointments for …
View article: Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT
Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT Open
Background High cure rates with licensed durations of therapy for chronic hepatitis C virus suggest that many patients are overtreated. New strategies in individuals who find it challenging to adhere to standard treatment courses could sig…
View article: P005 Evaluating the non-viral liver disease burden in people living with HIV and abnormal liver enzymes
P005 Evaluating the non-viral liver disease burden in people living with HIV and abnormal liver enzymes Open
Background Liver disease in the absence of viral hepatitis co-infection in people living with HIV (PLWH) is likely due to alcohol excess, metabolic syndrome (MS), and hepatotoxic antiretrovirals (ARV). We assessed the prevalence of hepatic…
View article: Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C Open
Background: The World Health Organization (WHO) has identified the need for a better understanding of which patients with hepatitis C virus (HCV) can be cured with ultrashort course HCV therapy. Methods: A total of 202 individuals with chr…
View article: Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C Open
Background: The world health organization (WHO) has identified the need for a better understanding of which patients with hepatitis C virus (HCV) can be cured with ultrashort course HCV therapy. Methods: A total of
View article: Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C
Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C Open
Background The WHO has identified the need for a better understanding of which patients can be cured with ultrashort course hepatitis C (HCV) therapy Methods 202 individuals with chronic HCV were randomised to fixed-duration shortened ther…
View article: P169 Long term abdominal drain for palliation in advance liver cirrhosis: survey of risks & barriers
P169 Long term abdominal drain for palliation in advance liver cirrhosis: survey of risks & barriers Open
Introduction Ascites is a leading cause of hospital admission in patients with cirrhosis, with up to a third developing refractory ascites (RA.) RA has a median transplant free survival of 6 months,1 yet palliation remains sub-o…
View article: Guidelines on the management of ascites in cirrhosis
Guidelines on the management of ascites in cirrhosis Open
The British Society of Gastroenterology in collaboration with British Association for the Study of the Liver has prepared this document. The aim of this guideline is to review and summarise the evidence that guides clinical diagnosis and m…
View article: Letter: long‐term abdominal drains in refractory ascites—evolving concept of palliative care in decompensated cirrhosis. Authors' reply
Letter: long‐term abdominal drains in refractory ascites—evolving concept of palliative care in decompensated cirrhosis. Authors' reply Open
LINKED CONTENT This article is linked to Macken et al and Roy et al papers. To view these articles, visit https://doi.org/10.1111/apt.15802 and https://doi.org/10.1111/apt.15944
View article: P1 Long term abdominal drain for palliation in advance liver cirrhosis: a survey of risks & barriers
P1 Long term abdominal drain for palliation in advance liver cirrhosis: a survey of risks & barriers Open
Introduction Ascites is a leading cause of hospital admission in patients with cirrhosis, with up to a third developing refractory ascites (RA.) RA has a median transplant free survival of 6 months,1 yet palliation remains sub-o…